UniSuper Management Pty Ltd Sells 13,826 Shares of United Therapeutics Co. (NASDAQ:UTHR)

UniSuper Management Pty Ltd lowered its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 94.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 800 shares of the biotechnology company's stock after selling 13,826 shares during the quarter. UniSuper Management Pty Ltd's holdings in United Therapeutics were worth $282,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the 4th quarter worth approximately $25,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB increased its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after buying an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in United Therapeutics in the 4th quarter worth $131,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on UTHR shares. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $388.25.

Remove Ads

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,500 shares of company stock valued at $26,134,500 in the last ninety days. Insiders own 11.90% of the company's stock.

United Therapeutics Trading Down 4.8 %

UTHR traded down $14.90 during trading hours on Friday, hitting $292.46. The company's stock had a trading volume of 579,460 shares, compared to its average volume of 450,601. United Therapeutics Co. has a 12 month low of $230.39 and a 12 month high of $417.82. The business's 50-day moving average price is $333.78 and its 200-day moving average price is $354.46. The stock has a market cap of $13.13 billion, a price-to-earnings ratio of 12.84, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company earned $4.36 EPS. On average, analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.